Biofrontera Posts Record Sales, Strategic Independence Amid Net Losses
ByAinvest
Tuesday, Sep 2, 2025 1:46 am ET1min read
BFRI--
Biofrontera reported record sales and strategic growth in Q2 2025, with total revenues of $9.0 million, a 15.4% increase from 2024. Sales of Ameluz exceeded 50,000 tubes, and lamp installations reached 40 in physician offices. The company also secured an $11 million investment, completed Phase III studies for actinic keratosis and superficial basal cell carcinoma, and received patent approval extending Ameluz's protection through 2043. However, Biofrontera reported a net loss of $5.3 million due to noncash fluctuations in the fair value of warrants.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet